Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
Contributo in Atti di convegno
Data di Pubblicazione:
2011
Tipologia CRIS:
04B-Conference paper in rivista
Elenco autori:
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson K; Esseltine DL; Liu K; Deraedt WM; Cakana AZ; van de Velde H; Richardson PG
Link alla scheda completa:
Pubblicato in: